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Introduction
The concept of targeted drug delivery is attractive because it 
recapitulates some of the advantages of topical application of 
drugs: high local concentration and low systemic exposure. 
In practice, this approach has met with some success but has 
not  provided  the  hoped-for  “silver  bullets.”  However,  recent   
developments in the field have rekindled interest in the targeting 
approach. We call this mode of drug delivery “synaphic” target-
ing; it is also referred to as pathotropic or active targeting. Cancer   
stands out as a disease most likely to benefit from targeted drug 
delivery. Tumor cells express many molecules on their surface 
that distinguish them from normal cells. Traditionally, such   
molecules were detected with antibodies, but screening of   
peptide and aptamer libraries has greatly expanded the number 
of tools available for selective binding to tumor cells (for reviews 
see Ruoslahti, 2002; Peer et al., 2007). Leukemia and lymphoma 
treatments with antibodies conjugated to a radioisotope have 
been in clinical use for several years (Sharkey and Goldenberg, 
2005). However, this approach has not been as successful with 
solid tumors. The apparent reason is the difficulty in deliv-
ering drugs into these tumors; drugs only penetrate a few cell   
diameters into the extravascular tumor tissue from blood vessels 
(Hambley and Hait, 2009). This low penetration appears to arise 
from two main factors: first, tumor vessels are poorly perfused 
with blood and are dysfunctional, which limits the delivery of 
blood-borne compounds to tumors (Jain, 1999). Second, tumors 
have a high interstitial pressure thought to result from dysfunc-
tional lymphatics, which causes tissue fluid to flow out of the 
tumor, working against diffusion of drugs from the blood vessels 
into the tumor (Jain, 1999; Heldin et al., 2004). The leakiness of 
tumor vessels partially makes up for the poor penetration (the 
so-called  enhanced  permeability  and  retention  [EPR]  effect),   
but EPR is not very effective, and its size dependency and   
variability from tumor to tumor limit its usefulness (Maeda et al., 
2000; Iyer et al., 2006; Sugahara et al., 2009). Interstitial fibrosis 
can further retard the diffusion of compounds through tumors 
(Olive et al., 2009). Targeting treatments to selective markers 
in tumor vessels does not suffer from some of these drawbacks 
of targeting tumor cells; in particular, no tissue penetration is   
required for the compound to reach its target. The luminal side of 
tumor vessels is fully accessible to compounds circulating in the 
blood, and the vessels can serve as a gateway to the tumor inte-
rior for compounds concentrated in the vessels. Using a targeting 
probe with tumor-penetrating properties and a receptor that is 
shared between tumor vessels and tumor cells provides additional   
advantages (Fig. 1). Thus, we have chosen to focus this review on 
targeting approaches that make use of specific markers in tumor 
vessels. We will also discuss solutions to the poor penetration of 
compounds into tumor tissue and the roles that nanoparticles can 
play in targeted therapies.
Molecular signatures in tumor vessels
Distinct  features  of  tumor  vessels.  Tumor  blood   
vessels are distinct from normal vessels. In addition to being 
tortuous, uneven in diameter, and leaky, tumor vessels express 
The various types of cells that comprise the tumor mass all 
carry molecular markers that are not expressed or are   
expressed at much lower levels in normal cells. These   
differentially expressed molecules can be used as docking 
sites to concentrate drug conjugates and nanoparticles at 
tumors. Specific markers in tumor vessels are particularly 
well suited for targeting because molecules at the surface 
of blood vessels are readily accessible to circulating   
compounds. The increased concentration of a drug in the 
site of disease made possible by targeted delivery can be 
used to increase efficacy, reduce side effects, or achieve 
some of both. We review the recent advances in this   
delivery approach with a focus on the use of molecular 
markers of tumor vasculature as the primary target and 
nanoparticles as the delivery vehicle.
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tumor-homing  peptides  with  RGD  (arginine/glycine/aspartice 
acid)  and  NGR  (asparagine/glycine/arginine)  motifs,  which 
had been previously identified in screens for integrin-binding 
peptides performed in vitro. F3 is an example of a novel tumor-
homing peptide identified by in vivo phage screening (Porkka 
et al., 2002). F3 binds to nucleolin, which is ubiquitous as an 
intracellular protein but is expressed at the cell surface of endo-
thelial cells and tumor cells in vivo (Christian et al., 2003).   
In vitro, all cells seem to be positive for cell surface nucleolin 
(Borer et al., 1989; Bonnet et al., 1996) presumably because cul-
tured cells resemble cells that have been activated in vivo. Cell   
surface nucleolin is an angiogenesis marker that is both a suit-
able target for drug delivery (Christian et al., 2001; Reddy et al., 
2006; Henke et al., 2008; Drecoll et al., 2009) and involved 
in the angiogenesis process (Fogal et al., 2009). The in vivo   
screening of phage libraries has also produced several potent 
tumor-homing peptides, the target molecules of which remain to 
be identified (Hoffman et al., 2003; Joyce et al., 2003; Järvinen 
and Ruoslahti, 2007; Chang et al., 2009).
The expression of intracellular proteins such as nucleolin   
at the cell surface of tumor cells and tumor endothelial cells 
appears to be a general principle. Phage display is particularly   
well suited for the discovery of such markers because the   
method inherently relies on binding to accessible targets on   
the cell surface rather than overall expression levels. In vivo cell   
surface  labeling  followed  by  monoclonal  antibody  production   
various  cell  surface  and  extracellular  matrix  proteins  that   
normal vessels do not express or do so at much lower levels 
than  tumor  vessels  (for  review  see  Ruoslahti,  2002).  The   
expression of many of these proteins in tumor vessels is asso-
ciated with angiogenesis, and they are often functionally impor-
tant in that process (Hanahan and Folkman, 1996; Alitalo and 
Carmeliet, 2002). Tumors also contain lymphatic vessels, and 
many tumors produce growth factors that stimulate lymph-
angiogenesis (Karpanen and Alitalo, 2008). Lymphatics are 
not necessary for tumor growth but are important conduits of   
metastasis. Like tumor blood vessels, tumor lymphatics can 
also express specific molecular markers.
Screening for markers in tumor vasculature. 
Screening of phage-displayed peptide libraries, particularly when 
performed in vivo, has provided a very useful discovery tool 
for vascular markers in tumor vessels and elsewhere (Pasqualini 
and Ruoslahti, 1996). A major advantage of the in vivo phage 
screening is that it is unbiased in revealing what works in   
vivo. Other unbiased methods, such as antibody-based screens 
(Jacobson et al., 1996), cloning strategies (Carson-Walter et al., 
2001), and in vivo biotinylation (Borgia et al., 2010), have also 
been used successfully in analyzing tumor vasculature. Phage 
screening has uncovered a large number of tumor-homing   
peptides that have been used to identify the corresponding 
binding protein (receptor). An early study on tumor-homing   
peptides (Arap et al., 1998) validated the method by producing 
Figure 1.  Synaphic targeting of tumors. The targeted receptors can be on tumor cells, tumor vessels, or shared by both. (A) Probes that recognize solely 
tumor cells provide little improvement of tumor accumulation over a nontargeted probe. (B) Probes that recognize tumor vessels accumulate in the tumor, 
but entry into tumor tissue relies on passive mechanisms. (C) Probes that recognize both the vessels and tumor cells combine the (limited) efficiency of the 
two targeting mechanisms. (D) Tumor-penetrating targeting probes (so far only peptides with such characteristics are known) provide a particularly potent 
targeting system.761 Targeting of drugs and nanoparticles to tumors • Ruoslahti et al.
nanoparticles: self-amplification of tumor homing (see Ampli-
fied tumor homing; Simberg et al., 2007).
Tumor  endothelial  markers  (TEMs). Surveying 
mRNA expression by the serial analysis of gene expression 
technique has revealed a large number of striking differences 
between endothelial cells isolated from human colon cancers 
and those from adjacent normal tissue (Carson-Walter et al., 
2001). Among these TEMs are collagens, some of which are 
expressed at strikingly high levels in tumor endothelial cells, at 
least at the mRNA level. The high collagen expression may   
relate to the extensive fibrosis found in many tumors and   
recently shown to contribute to the poor penetration of drugs 
into tumors (Olive et al., 2009). Perhaps the most interesting 
among the TEMs is TEM 8, which is one of the two receptors 
for the anthrax toxin (Nanda et al., 2004). An effort is under 
way to develop anthrax toxin variants that bind only to TEM 8 
and that could be used to target tumor vasculature for destruc-
tion. Table I provides a list of the principal cell surface markers 
available in tumor vessels for docking-based targeting.
Stage-specific markers. The molecular angiogenesis 
signatures vary depending on the state of tumor development. 
Initiation of angiogenesis (the angiogenic switch) occurs already 
in premalignant lesions (Hanahan and Folkman, 1996). Peptide 
probes that distinguish between the blood vessels of premalig-
nant and fully malignant lesions of some de novo cancers in 
mice have been reported (Hoffman et al., 2003; Joyce et al., 
2003). The vascular molecules recognized by these peptides re-
main to be identified. It may also be possible to develop targeting 
probes that distinguish between physiological and tumor angio-
genesis (Seaman et al., 2007).
Nontumor angiogenesis. A significant issue in the 
use of angiogenesis-detecting probes in cancer diagnosis or 
therapy is that angiogenesis also occurs in regenerating tissues 
and in inflammation. This poses a potential problem for tumor 
targeting, as angiogenesis associated with tissue repair in con-
ditions coexisting with cancer, such as myocardial infarction 
or stroke, could be inadvertently targeted for destruction.   
This circumstance emphasizes the need to discover vascular   
and proteomics analyses is another way of interrogating the   
cell surface. In addition to aforementioned nucleolin, the cyto-
plasmic proteins annexin1 (Oh et al., 2004) and plectin-1 (Kelly   
et al., 2008) have been found to be present at the cell surface   
of endothelial cells in tumors but not in normal tissues. Another   
example is p32 protein (gC1q receptor, hyaluronic acid–binding   
protein). This protein is primarily a mitochondrial protein, but it   
is also expressed at the cell surface of lymphatic, myeloid, and 
cancer cells in tumors but not in normal tissues (Fogal et al., 2008). 
This protein is the receptor for the tumor-homing peptide LyP-1, 
originally discovered using in vivo phage display (Laakkonen   
et al., 2002).
Adhesion receptors as angiogenesis markers. 
Some of the molecular markers in tumor vasculature have been 
found by studying the expression of known cell surface recep-
tors in tumor vessels. A prime example is the overexpression 
of v3 and v5 integrins in angiogenic vessels (Brooks   
et al., 1994; Erdreich-Epstein et al., 2000; Desgrosellier and 
Cheresh, 2010). These integrins are prime targets for synaphic 
drug delivery. Vascular markers expressed on the surface of the   
endothelium, such as the integrins, are most readily available 
for the binding of blood-borne compounds. However, the ECM 
also contains distinct markers that can be used in tumor target-
ing. An alternatively spliced form of fibronectin containing an   
additional type III domain, ED-B, is selectively expressed in 
tumor (and other) angiogenic vessels (Nilsson et al., 2001). Anti-
bodies to ED-B have been used to construct immunotoxins and 
other compounds for tumor targeting. Proteolytically processed 
type IV collagen is another matrix component that can be de-
tected with antibodies or peptides (Roth et al., 2006; Mueller et al., 
2009). The support cells (mural cells) in the vascular wall also 
contain markers that are specific for tumor vessels and that can 
be potentially useful in tumor targeting. NG2, a membrane-
spanning chondroitin sulfate proteoglycan, is a cell surface marker 
of pericytes (and smooth muscle cells) in angiogenic vessels 
not expressed in the pericytes of normal vessels (Stallcup and 
Huang, 2008). One of the PDFG receptors is another marker 
that is expressed at high levels in pericytes (Song et al., 2005).
Fibrin–fibronectin complexes in tumors. Peptides   
that specifically bind to fibrin–fibronectin complexes or other 
proteins associated with these complexes also home to tumors. 
The walls of tumor vessels and the interstitial spaces in tumors   
contain products of blood clotting, presumably as a result of 
plasma protein seepage from leaky tumor vessels. Leaked fibrin-
ogen is converted to a fibrin meshwork by tissue-procoagulant 
proteins such as tissue factor (Dvorak et al., 1985; Abe et al.,   
1999; Pilch et al., 2006). Other plasma proteins, plasma fibro-
nectin  in  particular,  become  covalently  linked  or  otherwise 
bound to the fibrin meshwork. These fibrin–fibronectin com-
plexes in the walls of tumor vessels and in the tumor intersti-
tial stroma can be accessed with peptides derived from phage   
screening,  such  as  the  nine–amino  acid  cyclic  peptide  CLT-1   
(Pilch et al., 2006; Ye et al., 2008) and the pentapeptide CREKA 
(Simberg et al., 2007). Fibrin-binding peptides isolated for 
the purpose of targeting blood clots in cardiovascular disease   
would presumably behave similarly if tested for tumor homing. 
The CREKA peptide has been used to confer a new function to 
Table I.  Cell surface and ECM-docking receptors in tumor vessels
Receptor References
RGD-directed integrins  
(v3 and v5)
Ruoslahti, 2002; Desgrosellier  
  and Cheresh, 2010
Aminopeptidase N Pasqualini et al., 2000
TEMs Carson-Walter et al., 2001
Endosialin Christian et al., 2001
Cell surface nucleolin Christian et al., 2003
Cell surface annexin-1 Oh et al., 2004
Cell surface p32/gC1q receptor Fogal et al., 2008
Cell surface plectin-1 Kelly et al., 2008
Fibronectin ED-B Nilsson et al., 2001
Fibrin–fibronectin complexes Pilch et al., 2006; Simberg  
  et al., 2007
Interleukin-11 receptor  Lewis et al., 2009
Protease-cleaved collagen IV Xu et al., 2001; Mueller  
  et al., 2009JCB • VOLUME 188 • NUMBER 6 • 2010   762
tissue factor to induce blood clotting specifically in tumor blood 
vessels, with resulting occlusion of the vessels and tumor   
necrosis (Bieker et al., 2009). A targeted TNF is currently in 
clinical trials (Paoloni et al. 2009; Gregorc et al., 2010).
Conjugates of an antibacterial peptide, which destroys 
mitochondria in mammalian cells causing apoptosis, with   
either the RGD or NGR peptide also inhibited tumor growth in 
mice, whereas either peptide alone was inactive (Ellerby et al., 
1999). Moreover, targeting the same proapoptotic peptide to 
the blood vessels of the normal prostate caused partial destruc-
tion of the prostate and delayed the development of cancers in 
transgenic prostate cancer mice (Arap et al., 2002). The poten-
tial of synaphic targeting is very well illustrated; the combina-
tion of homing peptides with nonselectively toxic compounds, 
such as proapoptotic peptides and TNF, can profoundly alter 
the in vivo activity of the toxins. RGD peptides and antibodies 
to v3 integrin have also been successfully used in targeted 
delivery of diagnostic probes to tumors (Sipkins et al., 1998;   
Stollman et al., 2009; Sugahara et al., 2009), and imaging 
probes based on this approach are in clinical trials. Drug-loaded 
nanoparticles have also been targeted with RGD peptides to 
suppress tumor growth or metastasis (Hood et al., 2002; Murphy 
et al., 2008; Sugahara et al., 2009). Finally, RGD and other 
tumor-homing peptides have been used to alter the host range 
of viral gene therapy vectors (Wickham, 2000; Haviv et al., 
2002). Several homing peptides that bind to receptors other 
than integrins have also been successfully used in preclinical 
studies to target gene therapy vectors, drugs, and biologicals 
into tumors (Müller et al., 2003; Hamzah et al., 2008; Chang 
et al., 2009; Karmali et al., 2009).
Tumor-penetrating  peptides.  A  major  problem 
with many of the currently used tumor-targeting probes is 
that a reagent directed to tumor cells will be impeded by 
the poor permeability of tumors to blood-borne compounds. 
This problem is particularly prominent with solid tumors, 
which have a high interstitial pressure, presumably because 
their  blood  vessels  tend  to  be  leaky  and  their  lymphatic   
vessels  poorly  functional  (Jain,  1999).  Drugs  generally  do 
not penetrate further than three to five cell diameters from 
blood  vessels,  which  leaves  more  distantly  located  tumor 
cells without any drug or exposes them to low drug concen-
trations that are likely to facilitate the development of resis-
tance (Hambley and Hait, 2009). Despite these limitations, a 
homing peptide that binds to the Her2 receptor (Gee et al., 
2008) has been used to deliver compounds to tumors that over-
express this receptor. Folic acid is another probe commonly 
used to target the folate receptor, which is overexpressed 
by tumor cells in many tumors (for review see Salazar and   
Ratnam, 2007). Experimental and theoretical results indicate 
that this increase in efficacy is not dominated by changes in 
overall drug uptake by the tumor (i.e., increased volumetric 
concentration) but rather changes in cellular internalization of 
the drug or how long it is retained in the tumor (Bartlett et al.,   
2007).  Thus,  there  is  little  or  no  specific  accumulation  of 
probes targeted solely to tumor cells (Fig. 1 A). Results with 
nanoparticles  targeted  to  tumor  cells  should  be  interpreted 
with particular care. Nanoparticles are small (from a few to 
markers with more focused target recognition properties. Probes 
that recognize tumor type–specific markers would fall into this 
category, as they obviously could not be targeting all forms of 
angiogenesis. The idea that this level of specificity can be 
achieved with tumor vessels has been demonstrated with tumor 
type–specific peptides (Hoffman et al., 2003; Joyce et al., 
2003; Laakkonen et al., 2004). Peptides like this should make 
diagnostic and therapeutic applications possible that are more 
selective than angiogenesis-based targeting. The use of pep-
tides (or other types of probes) with this kind of focused speci-
ficity would likely require first diagnostically assessing the 
tumor of each individual patient for the selective expression of 
the appropriate receptor. Such personalized medicine seems 
certain to become increasingly prevalent.
Functional role of tumor vessel markers. The 
v integrins play an important role in angiogenesis, although 
the details of their involvement in this process remain to be fully 
elucidated (Desgrosellier and Cheresh, 2010). Peptides contain-
ing an NGR sequence motif had previously been shown to bind 
weakly to the RGD-binding site of integrins (Koivunen et al., 
1994), but this motif was later identified as the binding motif 
in tumor-homing peptides that were more potent than could be 
expected on the basis of the weak integrin binding (Arap et al., 
1998). It was subsequently shown that the NGR peptides recog-
nize aminopeptidase N (Pasqualini et al., 2000) and potentially, 
after a chemical alteration, v integrins (Curnis et al., 2008). 
Like nucleolin, aminopeptidase N is functionally important in 
the angiogenesis process (Pasqualini et al., 2000; Rangel et al., 
2007). These findings serve as a paradigm to illustrate a dis-
covery process in which a new homing peptide is discovered 
in phage screening, the receptor for the peptide is identified 
by biochemical methods such as affinity chromatography, and 
subsequent studies reveal a role for the receptor in the biology 
of tumor vessels. Once the receptor is identified, an effective   
therapy may be engineered. Both F3 and the NGR motif peptides 
have been used to target drugs to tumors (Curnis et al., 2004; 
Reddy et al., 2006; Henke et al., 2008), and aptamers that bind 
nucleolin are being pursued in phase I clinical trials (Laber, D., 
V.R. Sharma, D.A. Laber, V.R. Sharma, L. Bhupalam, B. Taft, 
F.J. Hendler, and K.M. Barnhart. 2005. American Society of 
Clinical Oncology Annual Meeting Proceedings. Abstr. 3064).
Delivery of therapeutic agents  
to vascular targets
Targeting  integrins. The  v3  and  v5  integrins  are 
highly expressed in tumor endothelium, and their level of expres-
sion may be highest in the vessels of the most malignant tumors 
(Erdreich-Epstein et al., 2000). Enhanced drug delivery with 
vascular homing peptides has been accomplished using a cyclic 
peptide containing the integrin-binding RGD motif (CRGDC) 
to deliver doxorubicin to tumors (Arap et al., 1998).
Remarkable success in targeting the cytokine TNF into 
tumors has been reported with RGD and NGR peptides; the   
targeted cytokine was effective in doses as much as 1,000-fold 
lower than the usual dose and effectively mitigating side effects 
as a result of the high toxicity of this cytokine (Curnis et al., 
2004). These same peptides have also been used to deliver   763 Targeting of drugs and nanoparticles to tumors • Ruoslahti et al.
display any cell type specificity (Gump and Dowdy, 2007), the 
CendR tumor-homing peptides are tumor specific. Jiang et al. 
(2004) have described a peptide design in which a negatively 
charged sequence tethered to a cationic cell-penetrating pep-
tide blocks the cell-penetrating activity until a tumor protease 
cleaves the tether. The authors achieved a threefold increase in 
tumor homing. The greater tumor-homing selectivity of peptides 
derived from in vivo phage display such as iRGD (12-fold) is 
likely because of the presence of a homing sequence (RGD in 
iRGD) in these peptides (Sugahara et al., 2009).
Limitations of synaphic targeting
Receptor  capacity. An  important  factor  to  consider  in   
synaphic tumor targeting is the capacity of the receptors that 
are targeted by the probe. The number of cell surface recep-
tors and their availability determine how many molecules of a   
targeting compound can be specifically bound at the tumor site. 
Under ideal conditions (infinite binding affinity), the amount of 
compound that can be bound by the tumor equals the number 
of available receptors (assuming a 1:1 binding ratio and negli-
gible turnover). For example, assuming a tumor cell volume of 
one nanoliter and the presence of 100,000 receptors per cell, 
there would maximally only be a total of 0.166 nmol of recep-
tor per gram of tumor. The binding of the targeting ligand for 
the receptor is likely to have a high nanomolar to low micro-
molar disassociation constant, which means that more of the 
targeting compound has to be administered than can be accom-
modated by the receptors to drive the interaction toward bind-
ing and receptor saturation. Moreover, only a fraction of the 
receptors is likely to be available to bind a ligand introduced 
into the blood stream. Any excess of the targeting compound 
is going to be handled by the body like any other nontargeted 
compound. If the amount of free targeting compound substan-
tially exceeds the receptor-bound amount, the effect of specific 
targeting will be drowned out by nonspecific background. This 
circumstance, illustrated in Fig. 2, is underappreciated in the 
200 nm in diameter) particles that can serve as drug carriers 
and contrast agents (for imaging) in medicine. Although small 
in comparison with cells, nanoparticles are much larger than 
molecules and are less likely to penetrate the vascular wall and 
gain access to tumor cells than small molecular mass drugs or 
even antibodies. Tumor blood vessels are more readily avail-
able for targeting than the tumor cells and can mediate specific 
targeting (Fig. 1 B). It is not clear to what extent the Her2 
or folate receptors might be expressed on tumor endothelial 
cells, where they would contribute to the uptake of drugs by 
the tumor. Some other receptors used in synaphic targeting 
are expressed both in the tumor vessels and on tumor cells. 
Examples include v integrins and nucleolin. These dual tar-
geters are more effective than probes that recognize only the 
vessels or the tumor cells (Fig. 1 C). However, strategies to in-
crease overall tumor accumulation of drugs and nanoparticles 
are still needed. Targeting with tumor-penetrating peptides, 
particularly when the peptide binds both to the tumor endothe-
lium and the tumor cells, provides such a strategy (Fig. 1 D).
The laboratory of E. Ruoslahti has recently discovered a   
tissue–cell penetration system that makes it possible to derive 
peptides that not only home to a specific target tissue but 
also penetrate into that tissue. The peptides contain a tissue 
penetration motif, R/KXXR/K, which has to be exposed at the 
C terminus of a peptide (or protein) to be active (the C-end 
rule [CendR]; Teesalu et al., 2009). A tumor-homing CendR 
peptide contains both a tumor-specific homing sequence and 
a cryptic (not C terminal) CendR sequence. The homing sequence 
takes the peptide to the vascular endothelium in the target tis-
sue, where the peptide is proteolytically processed by an endog-
enous protease such that the CendR motif becomes C terminal 
and active. The activated CendR motif then binds to a dif-
ferent receptor (neuropilin-1), which mediates extravasation, 
tissue penetration, and cell entry of the C-terminally truncated 
peptide and any payload attached to it. An RGD containing a 
CendR motif, iRGD, exemplifies the capabilities of these pep-
tides. The iRGD peptide penetrates into tumor tissue and is 
capable of carrying 10 times more drug cargo into a tumor than 
a conventional RGD peptide (Sugahara et al., 2009).
Several aforementioned homing peptides may be tumor-
penetrating peptides similar to iRGD. F3 (Porkka et al., 2002), 
LyP-1 (Laakkonen et al., 2002), and CRGRRST (Joyce et al., 
2003) each contain a potential CendR sequence. Moreover, F3 
and LyP-1 have been shown to cause extravasation of their 
cargo, which can be as large as a nanoparticle, with subsequent 
uptake into tumor endothelial cells and tumor cells (Porkka   
et al., 2002; Laakkonen et al., 2004; Karmali et al., 2009). 
Coating of abraxane, which is a nanoparticle drug composed 
of paclitaxel and albumin, with the LyP-1 or iRGD peptide 
made the drug capable of penetrating into tumor tissue, re-
sulting in several-fold higher activity than that of the original 
drug (Karmali et al., 2009; Sugahara et al., 2009). The tissue- 
penetrating properties of these peptides and their internalization   
into cells makes them particularly efficient in achieving a high 
concentration of the peptide and any payload attached to it in   
tumor tissue. Unlike the cell-penetrating peptides related to   
the human immunodeficiency virus Tat protein, which do not   
Figure 2.  Saturation of receptors affects the specificity of synaphic target-
ing. Once the receptors of the homing peptide have been saturated, the 
specificity of the targeting declines (adapted from experimental data in 
Kranenborg et al., 1998). au, arbitrary units.JCB • VOLUME 188 • NUMBER 6 • 2010   764
receptors and that this may result in synergistic binding. It 
will be interesting to see whether other antitumor compounds 
with their own cell surface receptor, such as the Her2 anti-
body trastuzumab, would also benefit from homing peptide 
targeting in this manner.
The stability of targeting probes. Elimination from 
the circulation and degradation are among the main factors 
that determine the efficiency of a targeting probe. Short in vivo 
half-life can be an advantage in imaging because it quickly 
eliminates the background caused by excess probe. However, 
in drug targeting, short half-life gives the targeted drug less 
time to penetrate into the target tissue. Long circulation times 
are especially important when the target is outside the vascu-
lature, although tumor-penetrating peptides offer a potential 
solution to this problem (Sugahara et al., 2009). The half-life 
primarily depends on the rate of elimination into the urine 
(small  molecules)  and  uptake  by  the  RES  in  the  liver  and 
spleen (particles). Coupling a small molecular mass drug or 
probe to polyethylene glycol is commonly used to increase 
molecular mass above the kidney filtration cut-off size of 5 nm 
(Choi et al., 2007). Polyethylene glycol coating is also a strategy 
used to minimize elimination of protein therapeutics. Preventing 
RES uptake is particularly important when nanoparticles are 
used in drug delivery.
RES, which is also known as MPS, resides primarily in the 
liver, spleen, and lymph nodes. It eliminates foreign materials, 
particularly particles, including synthetic nanoparticles, from 
the  circulation.  Tumor-responsive,  cleavable  stealth  coatings 
have been used to mitigate this problem (Harris et al., 2008), 
but the RES/MPS uptake of nanoparticles remains a major 
problem in the use of nanoparticles in nanomedicine. It limits 
the amount of drug or probe that can reach the intended target, 
obscures the imaging of the liver and the organs near it, and 
is a source of potential liver toxicity. Coating of nanoparticles 
with plasma proteins that mediate binding to Kupffer cell recep-
tors in the liver is thought to underlie this phenomenon, but the   
unfortunate fact is that the molecular mechanisms of the uptake 
of nanoparticles by the RES are not really understood (for re-
view see Moghimi et al., 2001). It has been empirically shown 
that particle charge (anionic or neutral), size (<100 nm), and 
ability to prevent complement binding can reduce rates of RES 
uptake and extend circulation time in mice (for review see Peer 
et al., 2007). Other results suggest that the RES uptake may 
have little to do with plasma protein–mediated opsonization 
(Simberg et al., 2009). The likely explanation for why this has 
been such an intractable problem is that the Kupffer cell recep-
tors use multiple low affinity interactions to capture nano (and 
micro)-particles, rendering conventional receptor identification 
methods impotent in addressing this issue. The current stealth 
technologies to make nanoparticles unrecognizable by the RES 
only delay the inevitable uptake by this system. It is of major 
importance to nanomedicine that efficient ways of prolonging 
nanoparticle circulation be discovered.
Targeted delivery of nanoparticles
Regardless of the limitations of nanoparticles, nanoparticle tech-
nology offers an exciting platform for drug delivery: they can 
field, despite repeated demonstrations that targeted compounds 
are more differentially active when administered at low doses. 
One potential solution to this problem is to use higher affinity 
ligands for the targeting, but this strong binding can lead to 
reduced tumor penetration through the so-called binding site 
barrier (van Osdol et al., 1991; Thurber et al., 2008). Other 
potential solutions include using anticancer agents with higher 
potency than most current drugs, using nanoparticle delivery 
vehicles that deliver more drug per receptor occupied than one 
to one conjugates, or inducing more binding sites in the tumor 
(see Amplified tumor homing).
Monovalent  versus  multivalent  binding. Low affin-
ity of a ligand for its receptor can seriously limit the targeting 
efficiency or even make it unachievable. Making the low affinity 
ligand multivalent can circumvent this problem. Multiple weak 
interactions produce strong binding. Many natural processes, 
such as antibody interactions, rely on this principle. For example,   
because each of the six binding sites in IgM antibodies is gener-
ally of low affinity, IgM antibodies rely on multivalent binding. 
Cells adhere through multivalent interactions between integrins 
and adhesion proteins such as fibronectin. Phage display with 
cells in vitro or tissues in vivo as the target (Hoffman et al., 
2003) is a prime example of a system that probes this moder-
ate affinity, multivalent landscape. Thus, phage display comple-
ments other target discovery methods such as those based on 
antibodies (Jacobson et al., 1996; Oh et al., 2004) or cloning 
methods  (Seaman  et  al.,  2007).  The  enhanced  avidity  from 
multivalency is usually the result of an unaffected binding rate 
(on rate [kon]) but a reduction in off rate (koff) for the multiple 
interactions. Multivalency is important in nanoparticle-based 
targeting because nanoparticles generally carry more than one 
targeting ligand and are therefore capable of multivalent bind-
ing. This concept is particularly relevant for peptides, which 
typically bind to their targets with relatively modest (low micro-
molar) affinities. Reulen et al. (2009) converted a nonbinding 
variant of a collagen-binding protein into an active targeting 
probe by inserting multiple copies of the protein into a micelle, 
artificially producing a multivalent ensemble. The reported   
enhancements from multivalency are as large as 10
8 but are 
more typically 10–10
4. Interestingly, as few as four RGD   
peptides could provide a 25-fold enhancement in binding of a   
30-nm particle to endothelial cells, and just three folate groups 
led  to  a  2,500-fold  enhancement  in  dendrimer  binding  to  a 
surface (dendrimers are branched synthetic polymers that can 
form nanoparticles and present ligands in a multivalent fashion 
in which the valency can be readily controlled; Montet et al., 
2006; Hong et al., 2007). At the same time, multivalent peptide 
presentation can increase recognition of nanoparticles by the   
reticuloendothelial system (RES; also known as the mono-
nuclear phagocyte system [MPS]).
Multivalency may partially explain the remarkable 1,000-
fold increase in the antitumor activity of TNF observed when 
homing peptides recognizing tumor vessels were added to the 
protein (Curnis et al., 2004). TNF is a trimeric protein, which 
would render the homing peptide multivalent. Another factor 
in the increase of activity may be that the chimeric compound 
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As this system at this point only leverages the inherent proper-
ties of the targeted nanoparticles, it could be further engineered 
to carry a drug.
The ability of one structural type to perform multiple 
medical  diagnostic  or  therapeutic  functions  is  an  advanta-
geous characteristic of nanomaterials that cannot be achieved 
with organic small molecules. However, nanosystems that inte-
grate multiple functions into a single structure can display 
reduced efficacy of the separate functions because of space 
and surface chemistry limitations and increased susceptibil-
ity to phagocyte uptake. Engineering separate nanomaterials 
that synergistically cooperate in their functions, such as tumor 
homing, is a way of dealing with this problem. This approach 
is particularly advantageous in combination therapies, which 
are commonly used in cancer treatments
As  was  discussed  earlier,  it  would  be  advantageous  to 
create more binding sites for targeted delivery in a tumor,   
particularly if they are within the vascular space. We recently 
constructed a system that leverages a biological cascade in vivo 
to increase the available binding sites for targeted delivery.   
Plasmonic  nanomaterials,  such  as  gold  nanorods,  present   
exciting opportunities for such targeting combinations. These 
materials are metallic structures that efficiently convert opti-
cal radiation into heat by coupling into one or more plasmon 
modes (Hirsch et al., 2003; Hu et al., 2006). We have recently 
shown that photothermal heating mediated by tumor-targeted 
gold  nanorods  can  increase  binding  sites  for  targeted  deliv-
ery with thermosensitive drug carriers (Fig. 3; von Maltzahn   
et al., 2009; Park et al., 2010). Other biological cascades, such 
as the protease activity that activates CendR peptides in tumors   
incorporate  unique  functions  that  cannot  be  engineered  into 
simple drugs. Although both drugs and nanoparticles can be   
targeted to a tumor, nanoparticles can be engineered to perform 
more complex, cooperative targeting functions. We will next dis-
cuss self-amplified homing of nanoparticles and amplification 
of the targeting by nanoparticle combinations.
Amplified  tumor  homing. We have made use of a 
peptide  that  binds  to  fibrin–fibronectin  complexes  in  blood 
clots to design a nanoparticle that self-amplifies its own hom-
ing to tumors. Iron oxide nanoparticles coated with the CREKA 
peptide bind and accumulate in tumor vessels where they cause   
additional clotting (Simberg et al., 2007). The approach is sim-
ilar  to  clotting  induced  in  tumor  vessels  by  tumor-targeted   
tissue factor (Huang et al., 1997; Bieker et al., 2009) with the 
exception that the CREKA system is based on self-amplified 
nanoparticle homing. The clotting induced by the CREKA-
coated iron oxide particles creates more binding sites for the 
peptide, which causes more clotting and so on. The 20% occlu-
sion  of  tumor  vessels  initially  obtained  greatly  improved   
tumor  imaging.  Recent  modifications  in  the  system  have   
increased the occlusion rate to 60–70%, producing highly sig-
nificant inhibition of tumor growth (Agemy, L., K.N. Sugahara, 
V.R. Kotamraju, K. Gujraty, C. Aleman, R. Nussinov, and   
E. Ruoslahti. 2009. Proceedings of the 100th Annual Meeting 
of  the American Association  for  Cancer  Research. Abstr. 
3668). Importantly, although the CREKA nanoparticles are non-
specifically taken up in the RES, no clotting was seen in the   
vessels  of  the  RES  organs  (or  any  other  normal  organs),   
indicating that the clotting mechanism active in this self- 
amplifying targeting system requires the tumor environment. 
Figure  3.  Treating  tumors  with  cooperative 
nanoparticles. This scheme illustrates a method 
to  induce  cooperative  nanoparticle  behavior 
that results in more effective delivery of treat-
ments  to  tumors.  This  example  uses  a  two- 
component system consisting of gold nanorods 
and  targeted,  thermally  sensitive  liposomes. 
(A)  Passive  accumulation  of  gold  nanorods. 
The circulating nanorods passively accumulate 
in the tumor as a result of leakiness of the tumor 
vasculature (the EPR effect). (B) Laser irradia-
tion of nanorods activates tumor cells. The gold 
nanorods absorb laser energy, heating the sur-
rounding tissue. This localized rise in tempera-
ture increases tissue permeability and induces 
expression of receptor proteins on the surface 
of the tumor cells. (C) Targeted nanoparticles 
(liposomes)  bind  to  tumor.  Receptor-specific 
targeting  peptides  attached  onto  the  second-
ary nanoparticles allow these particles to bind 
to the overexpressed receptor proteins on the 
heat-activated tumor cells. (D) Activation of tar-
geted liposomes releases drug. In this example, 
thermally  responsive  liposomes  containing  a 
drug payload are heated with a second laser 
pulse,  inducing  rupture  of  the  liposome  shell 
and release of its contents.JCB • VOLUME 188 • NUMBER 6 • 2010   766
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